Articles tagged with Vaccine Development
A novel vaccination approach cleared harmful gut bacterium Clostridioides difficile (C. diff) in an animal model of infection. The experimental vaccine protected against illness, death, tissue damage and infection recurrence through mucosal immunization.
Researchers at Ragon Institute discovered that antibodies produced in germinal centers act as a 'brake' on selection, redirecting the immune system toward broader protection. Stronger-binding B cells suppress weaker ones targeting the same site, establishing a localized feedback loop.
A new HPV cancer vaccine developed by Northwestern University scientists has shown promising results in a preclinical model. The vaccine's carefully organized structure dramatically enhances the immune system's ability to attack tumors, shrinking them and extending animal survival.
Researchers have identified a molecular trigger for rare blood clotting conditions after COVID19 adenovirus-based vaccines or natural adenovirus infections. The exact cause is now understood, allowing vaccine developers to adjust the adenovirus protein and prevent this extremely rare reaction.
The partnership aims to develop next-generation mRNA vaccines with enhanced stability and targeted delivery, providing broader protection against emerging pathogens. This collaboration combines Ethris' mRNA technology platforms with DZIF's vaccine research expertise to accelerate the development of variant-ready vaccines.
A team of researchers at Binghamton University is developing a new yeast-based solution for the production of better avian flu vaccines. The project aims to improve manufacturing, storage, and transportation efficiency compared to current options.
Researchers developed an intranasal vaccine that elicited strong immune responses and prevented infections in exposed animals, providing protection against upper respiratory infection and severe disease. The nasal vaccine was effective regardless of prior flu exposure, making it a promising tool in the fight against H5N1 bird flu.
A new MERS vaccine candidate has shown a stable and functional immune response in humans that persists for at least two years after a booster vaccination. The study demonstrates that such durable immunity can be achieved through targeted booster vaccinations, providing an important step toward an effective MERS vaccine.
The new platform developed by UVA Health scientists can produce vaccines much faster, cheaper, and more easily than traditional approaches. The platform's proof-of-concept demonstrates its ability to produce highly immunogenic vaccines that can be manufactured at extremely low cost.
Researchers developed a new system that efficiently transfects targeted immune cells, supports antigen presentation and immune cell maturation, and successfully crosses the mucus barrier in lung models. This breakthrough offers a promising alternative to lipid nanoparticles for next-generation pulmonary mRNA vaccines.
A single-dose oral cholera vaccine called PanChol has completed a phase 1 clinical trial with positive results, offering hope for combating the devastating disease globally. The vaccine was developed by Mass General Brigham and shows promise in preventing severe vomiting and diarrhea caused by Vibrio cholerae bacteria.
A study published in JAMA found that nirsevimab was associated with lower risks of RSV-related hospitalization and severe outcomes compared to maternal vaccination with the RSVpreF vaccine. These findings suggest a potential benefit for passive infant immunization with nirsevimab in reducing RSV-related complications.
Researchers at Tulane University have developed the first vaccine able to protect nonhuman primates from melioidosis, a long-neglected and deadly tropical disease on the rise. The vaccine uses outer membrane vesicles to trigger a powerful immune response.
Two new Cochrane reviews show that HPV vaccines are effective in preventing cervical cancer and pre-cancerous changes, especially when given to young people before they are exposed to the virus. Girls vaccinated before the age of 16 were found to be 80% less likely to develop cervical cancer.
Scientists have developed a fast-acting and long-lasting vaccine against Crimean-Congo hemorrhagic fever (CCHF), which is one of the world's most dangerous infectious diseases. The vaccine, made from a virus-like replicon particle, provides durable humoral immunity for up to 18 months.
Researchers discovered a 'sticky' molecule, P-selectin, that can cause blood clots and organ failure during COVID-19. A new mRNA therapy that drives P-selectin expression provides broad protection against coronavirus infection.
Cynthia Nau Cornelissen has received nearly $7 million in federal grants to combat sexually transmitted infections (STIs), particularly gonorrhea. The researcher will study the human-specific pathogen Neisseria gonorrhoeae and develop vaccines and therapeutics using innovative approaches.
The Phase 3 study demonstrated the safety and non-inferiority of EuTYPH-C Inj.® Multi-dose compared to a World Health Organization (WHO) prequalified comparator TCV, Typbar TCV®. The vaccine was shown to be well-tolerated across all age groups with no serious adverse events.
A new nasally-delivered vaccine has been shown to prevent severe disease and curb bacterial transmission, addressing a global need for next-generation immunisation technologies. The vaccine targets the respiratory mucosa, providing stronger protection against respiratory infections.
Researchers have developed particles that can deliver an effective immune response at a much lower dose than traditional mRNA vaccines. The new particles, called AMG1541, use cyclic structures and ester groups to enhance mRNA delivery and improve biodegradability. This could potentially reduce vaccine costs and side effects.
Researchers at the University of Maryland School of Medicine have reported encouraging results from an early phase clinical trial of an intranasal influenza vaccine. The study found that the vaccine triggered a broad immune response, including higher levels of protective antibodies and better ability to kill infected cells.
Researchers at MIT have identified possible antigens for a new TB vaccine, stimulating a strong immune response in T cells. The study reveals 27 TB peptides that appear most often on infected cell surfaces and elicit a T cell response in at least some samples.
Researchers have discovered that human astroviruses bind to a protein in human cells called the neonatal Fc receptor. The study provides a key target for vaccine development and repurposing of existing treatments.
Researchers have developed a novel vaccine strategy using biomaterial scaffold vaccines to protect against Staphylococcus aureus infections in orthopedic device implants. The vaccines, made with immune cell-attaching molecules and S. aureus-specific antigens, create a beneficial immune response that significantly lowers bacterial burden.
Scientists have characterized lipid nanoparticles' internal shape and structure, which correlates with how well they deliver therapeutic cargo. The research provides a blueprint for engineering more effective RNA therapies by matching LNP designs to specific therapies and tissues.
The ESMO Congress 2025 will cover key topics including precision oncology, antibody-drug conjugates in breast cancer, dose optimisation strategies, new treatment modalities for melanoma, and immunotherapy-based approaches across various cancer settings. Promising Phase-3 studies on ADCs in bladder and lung cancer are also expected.
Researchers have developed a new mRNA vaccine technology using albumin-recruiting lipid nanoparticles to deliver vaccines precisely to lymph nodes, avoiding liver toxicity. The approach outperformed traditional delivery systems in laboratory tests, producing strong antitumor T-cell responses and high levels of neutralizing antibodies.
A new vaccine against elephant endotheliotropic herpesvirus (EEHV) has been shown to be safe and trigger a strong immune response, with the potential to prevent deadly EEHV disease in young Asian elephants. The vaccine was tested in adult elephants at Chester Zoo and successfully activated key parts of the immune system.
A new herpes virus-based vaccine has been developed that targets cancer cells while sparing healthy tissue. The vaccine, which includes a gene encoding the protein decorin, was shown to enhance its cancer-killing effect on lung cancer cells and reduce tumour angiogenesis in liver cancer in chicken embryos.
A new mRNA vaccine has stopped allergens from causing immune reactions and inflammation in mice, instructing the immune system to respond more appropriately. The vaccine is tailored to encode proteins from different allergens, offering a flexible solution to treat seasonal pollen allergies, food sensitivities, and asthma.
A new Cochrane review finds RSV vaccines reduce the risk of infection in vulnerable groups, including older adults and infants. Vaccination also significantly reduces severe disease and hospitalization rates.
Researchers developed an mRNA vaccine that suppresses abnormal blood vessel growth in mouse models of age-related macular degeneration. The vaccine is as effective as current therapies and offers a convenient alternative to frequent eye injections.
Stefan Kappe, a leading expert in genetic engineering of parasites, has been appointed as the new Director of the Center for Vaccine Development and Global Health at UM School of Medicine. He will focus on developing genetically engineered live-attenuated pathogens to combat malaria infection.
Researchers found that correcting myths with facts strengthened people's intentions to get vaccinated, making myth-busting strategies a key to broader vaccine distribution. The study suggests three effective strategies for debunking false information about COVID vaccines.
Researchers developed a high-volume method to rapidly build and test large numbers of antibodies at once, accelerating antibody research and treatment development. The oPool+ display platform has potential applications in influenza vaccination research, infectious disease treatment, and cancer research.
Researchers discovered that atherosclerotic plaques contain gelatinous biofilms formed by bacteria, which can trigger inflammation and rupture of the plaque leading to myocardial infarction. The study also validated an antibody targeting these bacteria, suggesting new diagnostic and therapeutic strategies for myocardial infarction.
A promising African swine fever vaccine candidate offers strong protection against one strain but fails to protect against others. The study highlights the need for region-specific vaccines and calls for further research into matching vaccines to virus types.
A new Zika virus vaccine developed by Brazilian researchers has been shown to be safe and effective in tests with mice, inducing an immune response and protecting against brain and testicular damage. The vaccine uses a technology known as 'virus-like particles' (VLPs) without genetic material from the pathogen.
Researchers at Texas Biomed have developed a live attenuated vaccine that showed high efficacy in cells and animal models, protecting mice from lethal H5N1. The team identified potential treatment targets using human airway organoids, revealing how bird flu remodels airway cells and causes scar tissue to form.
A new vaccine developed to protect against 21 strains of pneumococcus will be tested in a randomised controlled trial, aiming to provide greater protection for babies against serious infections. The trial is recruiting over 1600 babies across Australia and internationally.
MIT researchers have developed a method to reveal the inner workings of protein language models, which can accurately predict proteins suitable for drug or vaccine targets. By analyzing sparse representations of proteins, they identified key features that drive these predictions.
Researchers used machine-learning models to design nanoparticles that can deliver RNA to cells more efficiently. The approach accelerated the identification of optimal ingredient mixtures in lipid nanoparticles, leading to better delivery vehicles for RNA vaccines and mRNA therapies. This could dramatically speed up the development of ...
A new report from the Microbiology Society argues that vaccine deployment can slow AMR emergence. The UK Government is called upon to remove barriers and incentivize public-private collaboration for vaccine development.
A novel cancer vaccine has shown encouraging early results in patients with pancreatic and colorectal cancer, two of the most difficult-to-treat malignancies. The vaccine targets KRAS mutations found in about 25% of solid tumors and drives about 90% of pancreatic cancers and 50% of colorectal cancers.
This book delves into the scientific foundations of mucosal vaccine platforms, discussing immunological mechanisms, novel adjuvants, and real-world development challenges. It serves as a valuable resource for professionals and students in life sciences, immunology, and pharmacology.
The TherVacB vaccine aims to activate the natural immune response to eliminate the hepatitis B virus. In a new phase 1b/2a clinical trial, 81 patients will receive increasing doses of the vaccine components to determine its safety and effectiveness.
Researchers at Scripps Research Institute have developed a new microchip that can reveal how antibodies interact with viruses, allowing for faster and clearer insights into vaccine development. The technology offers a quicker-than-ever method to analyze antibody interactions, enabling scientists to design more effective vaccines.
Renowned vaccine expert Pierre Van Damme shared his experience leading over 500 clinical trials and establishing Vaccinopolis, a global research hub for vaccine clinical trials. The Vaccine Innovation Center of Korea University's College of Medicine aims to expand global cooperation in vaccine R&D through special seminars.
Researchers have discovered a way to enhance the effectiveness of mRNA vaccines by disguising them as virus-like particles, prompting a stronger immune response in mice. The innovation could lead to lower doses and longer-lasting immunity.
Researchers at MIT and Scripps Research Institute developed a vaccine that generates many more HIV-targeting B cells in mice with just one dose, using two adjuvants. The dual-adjuvant vaccine produces a wider diversity of antibodies against an HIV antigen, allowing the immune system to build up a stronger response.
Researchers have identified a critical step in SARS-CoV-2 viral infection: the protective role of ORF3a, which forms dense bodies surrounding the spike protein to prevent it from being cut into smaller components. This finding could lead to new therapeutic targets and vaccine development strategies.
The clinical trial demonstrated that the vaccine was safe and fully attenuated, causing no malaria infections in adults. The vaccine has the potential to achieve unprecedented potency and is designed to align with WHO's goals for malaria elimination.
A new mRNA vaccine has shown to be more effective and less costly to develop, inducing a robust immune response against SARS-CoV-2 variants. The vaccine's trans-amplifying platform allows for reduced production costs and potential broad protection.
The European Vaccines Hub for Pandemic Readiness (EVH) is a pan-European center that integrates excellence in vaccine research, human monoclonal antibody development, clinical trials, and scalable manufacturing. EVH aims to drive innovation and ensure strategic autonomy in vaccine R&D and manufacturing.
A study found that adults hospitalized for RSV had significantly higher odds of cardiac events compared to those with COVID-19 or influenza. The findings suggest that preexisting cardiovascular risk patients should consider vaccination against respiratory viral infections.
Researchers from the University of Cincinnati have engineered bacteria to deliver antiviral therapies and vaccines orally, bypassing traditional methods. The engineered bacteria use outer-membrane vesicles as self-propelled delivery vehicles, targeting mucosal surfaces to provide mucosal immunity.
Researchers from Amsterdam UMC have made a breakthrough in developing an HIV vaccine with a germline-targeting strategy, inducing immune responses in participants. The phase one trial showed promising results, suggesting the potential for this approach to be further developed into a vaccine.
Researchers discovered 500 cryptic peptides found only in pancreatic tumors, which could be targeted by vaccines or engineered T cells to attack the cancer. The peptides were identified using immunopeptidomics and shown to slow down tumor growth in mice.
Researchers from Japan evaluate the LC16m8 vaccine, an attenuated vaccinia virus strain, for its efficacy and safety against mpox. The study confirms the vaccine's ability to induce strong immune responses and protect against mpox in mice, monkeys, and humans.
A novel vaccine platform uses genetically fused antigen to albumin, which is actively transported across the mucosal barrier by FcRn receptor. This results in protective systemic and mucosal antibody responses against SARS-CoV-2 and influenza A.